Tag: axi-cel

ZUMA 7 Trial: Axi-Cel Therapy- A New Hope for Patients with Early Relapsed or Refractory Large B-Cell Lymphoma

ZUMA 7 Trial Summary Patients with early relapsed or refractory large B-cell lymphoma often face poor prognoses after receiving first-line chemoimmunotherapy. However, a recent international, phase 3 trial has demonstrated promising results with the use of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy. In this trial, patients with large B-cell lymphoma, […]